Research output per year
Research output per year
Personal profile
Expertises
Clinical oncology; Early clinical trials; Translational oncology; personalized medicin;
Main research areas
Phase 1 oncology trails; Early Phase 2 oncology trials; Translational medicin; Personalized medicin; Patient derived xenografts; Cancer drug screening
Current research
Phase 1 clinical trials and early phase 2 clinical trials.
Creation of PDX for cancer drug screening and application of the findings in patients.
Potential conflicts of interest
None
Fingerprint
Dive into the research topics where Kristoffer Staal Rohrberg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Melero, I., Tanos, T., Bustamante, M., Sanmamed, M. F., Calvo, E., Moreno, I., Moreno, V., Hernandez, T., Martinez Garcia, M., Rodriguez-Vida, A., Tabernero, J., Azaro, A., Ponz-Sarvisé, M., Spanggaard, I., Rohrberg, K., Guarin, E., Nüesch, E., Davydov, I. I., Ooi, C., Duarte, J., & 5 others, 10 May 2023, In: Science translational medicine. 15, 695, p. eabp9229 abp9229.Research output: Contribution to journal › Journal article › Research › peer-review
-
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
Yap, T. A., Bardia, A., Dvorkin, M., Galsky, M. D., Beck, J. T., Wise, D. R., Karyakin, O., Rubovszky, G., Kislov, N., Rohrberg, K., Joy, A. A., Telli, M. L., Schram, A. M., Conte, U., Chappey, C., Stewart, R., Stypinski, D., Michelon, E., Cesari, R. & Konstantinopoulos, P. A., 1 Jan 2023, In: JAMA Oncology. 9, 1, p. 40-50 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
New pathogenic germline variants identified in mesothelioma
Belcaid, L., Bertelsen, B., Wadt, K., Tuxen, I., Spanggaard, I., Højgaard, M., Benn Sørensen, J., Ravn, J., Lassen, U., Cilius Nielsen, F., Rohrberg, K. & Westmose Yde, C., 15 Mar 2023, (E-pub ahead of print) In: Lung Cancer. 179, p. 107172 107172.Research output: Contribution to journal › Review › peer-review
-
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
Kringelbach, T., Højgaard, M., Rohrberg, K., Spanggaard, I., Laursen, B. E., Ladekarl, M., Haslund, C. A., Harsløf, L., Belcaid, L., Gehl, J., Søndergaard, L., Eefsen, R. L., Hansen, K. H., Kodahl, A. R., Jensen, L. H., Holt, M. I., Oellegaard, T. H., Yde, C. W., Ahlborn, L. B. & Lassen, U., 22 Feb 2023, In: BMC Cancer. 23, 1, 182.Research output: Contribution to journal › Journal article › Research › peer-review
-
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade
Nazerai, L., Willis, S. C., Yankilevich, P., Di Leo, L., Bosisio, F. M., Frias, A., Bertolotto, C., Nersting, J., Thastrup, M., Buus, S., Thomsen, A. R., Nielsen, M., Rohrberg, K. S., Schmiegelow, K. & De Zio, D., 2023, In: OncoImmunology. 12, 1, p. 2158610 2158610.Research output: Contribution to journal › Journal article › Research › peer-review